Skip to main content Accessibility help
×
Hostname: page-component-5d59c44645-k78ct Total loading time: 0 Render date: 2024-02-20T16:55:30.173Z Has data issue: false hasContentIssue false

Chapter 62 - Infections in Oncology Patients

Published online by Cambridge University Press:  23 July 2018

Rachel L. Chin
Affiliation:
University of California, San Francisco School of Medicine
Bradley W. Frazee
Affiliation:
University of California, San Francisco School of Medicine
Zlatan Coralic
Affiliation:
University of California, San Francisco
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baden, L. R., Bensinger, W., Angarone, M., et al. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections, Version 2, 2014, available at www.NCCN.org (accessed March 1, 2015).Google Scholar
Behre, G., Link, H., Maschmeyer, G., et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann. Hematol. 1998; 76(2): 7380. (Neutropenic fever trial)CrossRefGoogle ScholarPubMed
Bodey, G. P., Buckley, M., Sathe, Y. S., and Freireich, EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med. 1966; 64(2): 328–40. (Study of relationship between severity and length of neutropenia and risk of infection)CrossRefGoogle ScholarPubMed
Bodro, M., Gudiol, C., Garcia-Vidal, C., et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. Support Care Cancer 2014; 22(3): 603–10. (Prospective observational study in oncology patients with bacteremia)CrossRefGoogle ScholarPubMed
Bow, E. J. There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J. Antimicrob. Chemother. 2013; 68(3): 492–5. (Review on multidrug-resistant organisms in cancer patients)CrossRefGoogle Scholar
Cometta, A., Calandra, T., Gaya, H., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto Infection Program. Antimicrob. Agents Chemother. 1996; 40(5): 1108–15. (Neutropenic fever trial)CrossRefGoogle ScholarPubMed
Cometta, A., Kern, W. V., de Bock, R., et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin. Infect. Dis. 2003; 37(3): 382–9. (Neutropenic fever trial)CrossRefGoogle ScholarPubMed
Cox, A. L., Thompson, S. A., Jones, J. L., et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 2005; 35(11): 3332–42. (Study evaluating duration of lymphopenia after alemtuzumab administration)CrossRefGoogle ScholarPubMed
Dubberke, E. R., Augustine, K., Olsen, M. A., et al. Epidemiology of bloodstream infections on a hematopoietic stem cell transplant unit. Infect. Dis. Soc. Am. 2004; abstract no. 648. (Study of the epidemiology of bloodstream infections in patients undergoing stem cell transplantation)Google Scholar
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 2011; 52(4): e56–93. (Infectious Diseases Society of America neutropenic fever guidelines)CrossRefGoogle ScholarPubMed
Freifeld, A., Marchigiani, D., Walsh, T., et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N. Engl. J. Med. 1999; 341(5): 305–11. (Study comparing oral antibiotics to IV antibiotics in low-risk febrile neutropenic patients)CrossRefGoogle ScholarPubMed
Hasbun, R., Abrahams, J., Jekel, J., and Quagliarello, V. J. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N. Engl. J. Med. 2001; 345(24): 1727–33. (Study of which patients should have a CT of the head performed before lumbar puncture)CrossRefGoogle ScholarPubMed
Kern, W. V., Cometta, A., de Bock, R., et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N. Engl. J. Med. 1999; 341(5): 312–18. (Study comparing oral antibiotics to IV antibiotics in low-risk febrile neutropenic patients)CrossRefGoogle ScholarPubMed
Klastersky, J., Paesmans, M., Rubenstein, E. B., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J. Clin. Oncol. 2000; 18(16): 3038–51. (Study to identify neutropenic patients at low-risk for complications)CrossRefGoogle ScholarPubMed
Klastersky, J. and Paesmans, M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013; 21(5): 1487–95. (Update from previous study on how to identify neutropenic patients at low-risk for complications)CrossRefGoogle ScholarPubMed
Kyriacou, D. N., Jovanovic, B., and Frankfurt, O. Timing of initial antibiotic treatment for febrile neutropenia in the emergency department: the need for evidence-based guidelines. J. Natl. Compr. Canc. Netw. 2014; 12(11): 1569–73.CrossRefGoogle ScholarPubMed
Montassier, E., Batard, E., Gastinne, T., et al. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2013; 32(7): 841–50. (Review of antibiotic resistant bacteremia in cancer patients)CrossRefGoogle Scholar
Neuburger, S. and Maschmeyer, G. Update on management of infections in cancer and stem cell transplant patients. Ann. Hematol. 2006; 85(6): 345–56. (Review of infections in leukemic patients and patient undergoing stem cell transplantation)CrossRefGoogle ScholarPubMed
Penack, O., Becker, C., Buchheidt, D., et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann. Hematol. 2014; 93(7): 1083–95. (Review of sepsis in patients with neutropenia and sepsis)CrossRefGoogle ScholarPubMed
Satlin, M. J., Calfee, D. P., Chen, L., et al. Emergence of carbapenem-resistant enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk. Lymphoma 2013; 54(4): 799806. (Retrospective review of patients with carbapenem-resistant Enterobacteriaceae bloodstream infections in patients with hematological malignancies)CrossRefGoogle ScholarPubMed
Sickles, E. A., Greene, W. H., and Wiernik, P. H. Clinical presentation of infection in granulocytopenic patients. Arch. Intern. Med. 1975; 135(5): 715–19. (Study of presentation of neutropenic patients with infections)CrossRefGoogle ScholarPubMed
Suster, S. and Rosen, L. B. Intradermal bullous dermatitis due to candidiasis in an immunocompromised patient. JAMA 1987; 258(15): 2106–7. (Case and review of neutropenic patients who develop subcutaneous nodules after candidemia)CrossRefGoogle Scholar
Tamura, K., Matsuoka, H., Tsukada, J., et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am. J. Hematol. 2002; 71(4): 248–55. (Neutropenic fever trial)CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×